Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Pipeline Review, H1 2018
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Pipeline Review, H1 2018
SUMMARY
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) pipeline Target constitutes close to 36 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The latest report Indoleamine 2,3 Dioxygenase 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Indoleamine-pyrrole 2, 3-dioxygenase 1 is a heme-containing enzyme encoded by the IDO1 gene. This enzyme acts on multiple tryptophan substrates including D-tryptophan, L-tryptophan, 5-hydroxy-tryptophan, tryptamine, and serotonin.
This enzyme plays a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immuno regulation, and antioxidant activity. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 2, 7, 3, 11 and 4 respectively.
Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 5 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal and Metabolic Disorders which include indications Solid Tumor, Non-Small Cell Lung Cancer, Metastatic Melanoma, Glioblastoma Multiforme (GBM), Bladder Cancer, Adenocarcinoma, Breast Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Advanced Malignancy, Alopecia, B-Cell Non-Hodgkin Lymphoma, Brain Cancer, Cervical Cancer, Colon Cancer, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Ependymoma, Gastric Cancer, Glioma, Gliosarcoma, Head And Neck Cancer, Hematological Tumor, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Inflammatory Bowel Disease, Lung Cancer, Malignant Glioma, Medulloblastoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Renal Cell Carcinoma, Ocular Melanoma, Ovarian Cancer, Psoriasis, Renal Cell Carcinoma, Squamous Cell Carcinoma, Transitional Cell Cancer (Urothelial Cell Cancer) and Type 1 Diabetes (Juvenile Diabetes).
Furthermore, this report also reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) pipeline Target constitutes close to 36 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The latest report Indoleamine 2,3 Dioxygenase 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Indoleamine-pyrrole 2, 3-dioxygenase 1 is a heme-containing enzyme encoded by the IDO1 gene. This enzyme acts on multiple tryptophan substrates including D-tryptophan, L-tryptophan, 5-hydroxy-tryptophan, tryptamine, and serotonin.
This enzyme plays a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immuno regulation, and antioxidant activity. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 2, 7, 3, 11 and 4 respectively.
Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 5 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal and Metabolic Disorders which include indications Solid Tumor, Non-Small Cell Lung Cancer, Metastatic Melanoma, Glioblastoma Multiforme (GBM), Bladder Cancer, Adenocarcinoma, Breast Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Advanced Malignancy, Alopecia, B-Cell Non-Hodgkin Lymphoma, Brain Cancer, Cervical Cancer, Colon Cancer, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Ependymoma, Gastric Cancer, Glioma, Gliosarcoma, Head And Neck Cancer, Hematological Tumor, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Inflammatory Bowel Disease, Lung Cancer, Malignant Glioma, Medulloblastoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Renal Cell Carcinoma, Ocular Melanoma, Ovarian Cancer, Psoriasis, Renal Cell Carcinoma, Squamous Cell Carcinoma, Transitional Cell Cancer (Urothelial Cell Cancer) and Type 1 Diabetes (Juvenile Diabetes).
Furthermore, this report also reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)
- The report reviews Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics and enlists all their major and minor projects
- The report assesses Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Overview
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Companies Involved in Therapeutics Development
BeiGene Ltd
BirchBioMed Inc
Bristol-Myers Squibb Co
CanBas Co Ltd
Eli Lilly and Co
Ensemble Therapeutics Corp
F. Hoffmann-La Roche Ltd
Incyte Corp
Innovent Biologics Inc
IO Biotech ApS
iTeos Therapeutics SA
Jiangsu Hengrui Medicine Co Ltd
Kyowa Hakko Kirin Co Ltd
Luye Pharma Group Ltd
Netherlands Translational Research Center BV
NewLink Genetics Corp
Regen BioPharma Inc
Tempest Therapeutics Inc
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Drug Profiles
AI-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGB-5777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dCellVax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DN-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DN-1406131 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EOS-200271 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epacadostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galanal - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTI-1090 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
indoximod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IO-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IO-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KHK-2455 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-01013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3381916 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-7162 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit IDO and TDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLG-802 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Inhibit IDO1 for Pancreatic Ductal Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-70099 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit IDO1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Indoleamine 2,3-Dioxygenase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Indoleamine 2,3-Dioxygenase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO and TDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO for Oncology and Gastrointestinal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO for Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO-1 for Lewis Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO-1 for Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO/TDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO1 and DNA for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRX-3217 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPST-8844 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target PDL1 and IDO for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Dormant Products
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Discontinued Products
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Product Development Milestones
Featured News & Press Releases
Mar 14, 2018: NewLink Genetics Announces Presentation of Abstracts at AACR Annual Meeting
Feb 09, 2018: iTeos Therapeutics Provides Update on its IDO1 Inhibitor EOS200271 at Molecular Medicine Tri-Conference
Jan 08, 2018: NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors
Nov 20, 2017: NewLink Genetics Announces the Presentation of Indoximod Data in Phase 1 Study for Children
Nov 13, 2017: IO Biotech Presented Posters on Preclinical Studies of Melanoma Drug Candidate IO102 at SITC Annual Meeting
Oct 30, 2017: NewLink Genetics Announces FDA Orphan-Drug Designation for Indoximod
Oct 12, 2017: IO Biotech Appoints Dr. Eva Ehrnrooth as Chief Medical Officer
Sep 09, 2017: Progression-Free Survival Data from ECHO-202 Trial of Incyte's Epacadostat in Combination with Merck's KEYTRUDA (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma
Sep 07, 2017: Updated Data for Indoximod Plus KEYTRUDA Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma
Aug 30, 2017: New Data for Epacadostat in Combination with KEYTRUDA (pembrolizumab) Demonstrate Durable Responses in Patients with Advanced Melanoma
Jul 28, 2017: NewLink Genetics provides Updates of Indoximod Program
Jul 27, 2017: NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802
Jul 10, 2017: NewLink Genetics Receives Notice of Allowance from USPTO Covering Indoximod Salts and Prodrugs
Jun 23, 2017: Positive Phase 1b Data for NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia Presented at the European Hematologic Association Congress in Madrid, Spain
Jun 05, 2017: NewLink Genetics' Indoximod + PROVENGE Results in Statistically Significant Improvement in Radiographic Progression-Free Survival for Patients with Metastatic Castration Resistant Prostate Cancer in Phase 2 Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Overview
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Companies Involved in Therapeutics Development
BeiGene Ltd
BirchBioMed Inc
Bristol-Myers Squibb Co
CanBas Co Ltd
Eli Lilly and Co
Ensemble Therapeutics Corp
F. Hoffmann-La Roche Ltd
Incyte Corp
Innovent Biologics Inc
IO Biotech ApS
iTeos Therapeutics SA
Jiangsu Hengrui Medicine Co Ltd
Kyowa Hakko Kirin Co Ltd
Luye Pharma Group Ltd
Netherlands Translational Research Center BV
NewLink Genetics Corp
Regen BioPharma Inc
Tempest Therapeutics Inc
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Drug Profiles
AI-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGB-5777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dCellVax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DN-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DN-1406131 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EOS-200271 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epacadostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galanal - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTI-1090 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
indoximod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IO-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IO-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KHK-2455 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-01013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3381916 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-7162 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit IDO and TDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLG-802 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Inhibit IDO1 for Pancreatic Ductal Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-70099 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit IDO1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Indoleamine 2,3-Dioxygenase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Indoleamine 2,3-Dioxygenase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO and TDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO for Oncology and Gastrointestinal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO for Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO-1 for Lewis Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO-1 for Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO/TDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO1 and DNA for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRX-3217 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPST-8844 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target PDL1 and IDO for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Dormant Products
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Discontinued Products
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Product Development Milestones
Featured News & Press Releases
Mar 14, 2018: NewLink Genetics Announces Presentation of Abstracts at AACR Annual Meeting
Feb 09, 2018: iTeos Therapeutics Provides Update on its IDO1 Inhibitor EOS200271 at Molecular Medicine Tri-Conference
Jan 08, 2018: NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors
Nov 20, 2017: NewLink Genetics Announces the Presentation of Indoximod Data in Phase 1 Study for Children
Nov 13, 2017: IO Biotech Presented Posters on Preclinical Studies of Melanoma Drug Candidate IO102 at SITC Annual Meeting
Oct 30, 2017: NewLink Genetics Announces FDA Orphan-Drug Designation for Indoximod
Oct 12, 2017: IO Biotech Appoints Dr. Eva Ehrnrooth as Chief Medical Officer
Sep 09, 2017: Progression-Free Survival Data from ECHO-202 Trial of Incyte's Epacadostat in Combination with Merck's KEYTRUDA (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma
Sep 07, 2017: Updated Data for Indoximod Plus KEYTRUDA Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma
Aug 30, 2017: New Data for Epacadostat in Combination with KEYTRUDA (pembrolizumab) Demonstrate Durable Responses in Patients with Advanced Melanoma
Jul 28, 2017: NewLink Genetics provides Updates of Indoximod Program
Jul 27, 2017: NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802
Jul 10, 2017: NewLink Genetics Receives Notice of Allowance from USPTO Covering Indoximod Salts and Prodrugs
Jun 23, 2017: Positive Phase 1b Data for NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia Presented at the European Hematologic Association Congress in Madrid, Spain
Jun 05, 2017: NewLink Genetics' Indoximod + PROVENGE Results in Statistically Significant Improvement in Radiographic Progression-Free Survival for Patients with Metastatic Castration Resistant Prostate Cancer in Phase 2 Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1)
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by BeiGene Ltd, H1 2018
Pipeline by BirchBioMed Inc, H1 2018
Pipeline by Bristol-Myers Squibb Co, H1 2018
Pipeline by CanBas Co Ltd, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by Ensemble Therapeutics Corp, H1 2018
Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Pipeline by Incyte Corp, H1 2018
Pipeline by Innovent Biologics Inc, H1 2018
Pipeline by IO Biotech ApS, H1 2018
Pipeline by iTeos Therapeutics SA, H1 2018
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018
Pipeline by Luye Pharma Group Ltd, H1 2018
Pipeline by Netherlands Translational Research Center BV, H1 2018
Pipeline by NewLink Genetics Corp, H1 2018
Pipeline by Regen BioPharma Inc, H1 2018
Pipeline by Tempest Therapeutics Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1)
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by BeiGene Ltd, H1 2018
Pipeline by BirchBioMed Inc, H1 2018
Pipeline by Bristol-Myers Squibb Co, H1 2018
Pipeline by CanBas Co Ltd, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by Ensemble Therapeutics Corp, H1 2018
Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Pipeline by Incyte Corp, H1 2018
Pipeline by Innovent Biologics Inc, H1 2018
Pipeline by IO Biotech ApS, H1 2018
Pipeline by iTeos Therapeutics SA, H1 2018
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018
Pipeline by Luye Pharma Group Ltd, H1 2018
Pipeline by Netherlands Translational Research Center BV, H1 2018
Pipeline by NewLink Genetics Corp, H1 2018
Pipeline by Regen BioPharma Inc, H1 2018
Pipeline by Tempest Therapeutics Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
COMPANIES MENTIONED
BeiGene Ltd
BirchBioMed Inc
Bristol-Myers Squibb Co
CanBas Co Ltd
Eli Lilly and Co
Ensemble Therapeutics Corp
F. Hoffmann-La Roche Ltd
Incyte Corp
Innovent Biologics Inc
IO Biotech ApS
iTeos Therapeutics SA
Jiangsu Hengrui Medicine Co Ltd
Kyowa Hakko Kirin Co Ltd
Luye Pharma Group Ltd
Netherlands Translational Research Center BV
NewLink Genetics Corp
Regen BioPharma Inc
Tempest Therapeutics Inc
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
COMPANIES MENTIONED
BeiGene Ltd
BirchBioMed Inc
Bristol-Myers Squibb Co
CanBas Co Ltd
Eli Lilly and Co
Ensemble Therapeutics Corp
F. Hoffmann-La Roche Ltd
Incyte Corp
Innovent Biologics Inc
IO Biotech ApS
iTeos Therapeutics SA
Jiangsu Hengrui Medicine Co Ltd
Kyowa Hakko Kirin Co Ltd
Luye Pharma Group Ltd
Netherlands Translational Research Center BV
NewLink Genetics Corp
Regen BioPharma Inc
Tempest Therapeutics Inc
